Straumann Holding AG (SAUHF)
136.02
+7.63
(+5.95%)
USD |
OTCM |
Dec 17, 13:15
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 21.69B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -17.69% |
| Valuation | |
| PE Ratio | 72.57 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.644 |
| Price to Book Value | 9.906 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.9321 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 61.15% |
Profile
| Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company’s core products are dental implants, and it holds nearly 30% of the global implant dentistry market, which is estimated to be worth roughly CHF 5.2 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 12% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands. |
| URL | https://www.straumann-group.com |
| Investor Relations URL | https://www.straumann.com/group/en/home/investors.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 14, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 16, 2024 |
Ratings
Profile
| Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company’s core products are dental implants, and it holds nearly 30% of the global implant dentistry market, which is estimated to be worth roughly CHF 5.2 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 12% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands. |
| URL | https://www.straumann-group.com |
| Investor Relations URL | https://www.straumann.com/group/en/home/investors.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 14, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 16, 2024 |